Investment
Features
FeesSafety
Academy
More
Pluang+

SEI Investments posts strong Q2 with 38% EPS growth, driving BUY rating despite 35% YTD rally.

Company Fundamentals
28 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

SEI Investments Company reported robust Q2 2026 results, exceeding expectations with a 38% increase in adjusted EPS and 36% growth in operating income, driven by strong performance in alternative and private equity markets. The company benefits from accelerating operating leverage, double-digit revenue growth in key segments, and maintains high cash flow with low debt. SEI also declared record dividends and has a strong pipeline of deals, supporting further growth potential. Despite a 35% rally year-to-date, the stock trades at a 22% discount to its 10-year peak valuation, suggesting room for multiple expansion based on forward EBITDA growth prospects.

More News

SEC approves Evernorth's $1B Nasdaq listing under XRPN despite XRP market slump

SEC approves Evernorth's $1B Nasdaq listing under XRPN despite XRP market slump

The U.S. SEC has approved Evernorth's registration, clearing the way for its $1 billion Nasdaq listing under the ticker XRPN through a merger with Armada Acquisition Corp. II. Evernorth plans to actively manage its XRP treasury to generate yield and ...

Market News
Bullish
4 hours ago
Amprius Technologies posts 125.7% revenue growth, raises 2026 guidance amid rising drone battery demand

Amprius Technologies posts 125.7% revenue growth, raises 2026 guidance amid rising drone battery demand

Amprius Technologies is benefiting from strong demand for drone batteries, reporting a 125.7% year-over-year revenue increase and improved gross margins. The company raised its 2026 revenue forecast to at least $140 million and aims for $600 million ...

Analyst Insights
Bullish
4 hours ago
INmune Bio undervalued as Ebstrocel for RDEB nears key regulatory milestones with $67M market cap.

INmune Bio undervalued as Ebstrocel for RDEB nears key regulatory milestones with $67M market cap.

INmune Bio is considered significantly undervalued with its treatment Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) driving a strong investment case. Ebstrocel offers systemic itch reduction, setting it apart from competitors like K...

Market News
Bullish
4 hours ago
PayPal stock plunges 14.67% after Stripe and Advent withdraw $60.50/share acquisition offer

PayPal stock plunges 14.67% after Stripe and Advent withdraw $60.50/share acquisition offer

PayPal's stock dropped sharply by 14.67% to $52.45 after Stripe and Advent withdrew their $60.50 per share acquisition offer, causing the company's market value to fall from $52.58 billion to $44.87 billion. This reversal ended the summer rally drive...

Market News
Bearish
4 hours ago
Ripple plans to retire unused XRPL native bridge code, cutting 10,000+ lines from its codebase.

Ripple plans to retire unused XRPL native bridge code, cutting 10,000+ lines from its codebase.

Ripple has recommended retiring the XLS-38 amendment, a native cross-chain bridge for the XRP Ledger that never activated on mainnet due to low validator support and Axelar handling XRPL-EVM bridging. This move will remove over 10,000 lines of unused...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App